My ePortfolio Register   

BGIICC 2018 /
Immuno-oncology in breast and cervical cancer

18th - 19th Jan 2018

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 29.01.18
Views: 480
Rating:

Prof Neal Ready - Duke University School of Medicine, Durham, USA

Prof Ready speaks with ecancer at the 10th BGICC in Cairo about recent advances with immunotherapy treatments to improve efficacy, reduce toxicity, and widen eligibility.

He outlines the growing number of indications in which checkpoint targeted agents are changing care, and how this may translate to typically non-immunogenic breast tumours.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence